Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 7;35(35):e284.
doi: 10.3346/jkms.2020.35.e284.

Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation

Doosoo Jeon  1 , Hyungseok Kang  2 , Yong Soo Kwon  3 , Jae Joon Yim  4 , Tae Sun Shim  5
Affiliations

Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation

Doosoo Jeon et al. J Korean Med Sci. .

Abstract

Background: The purpose of this study was to evaluate the current status and trends in the coverage of molecular drug susceptibility testing (mDST), and the impact of mDST on the time to multidrug-resistant tuberculosis (MDR-TB) treatment initiation in Korea.

Methods: We included confirmed rifampin-resistant (RR)/MDR-TB patients who submitted application forms for novel drug uses to the National TB Expert Review Committee from September 1, 2016 to November 30, 2019. We retrospectively reviewed their medical records.

Results: Of the 621 MDR/RR-TB patients, mDST was performed in 442 (71.2%); Xpert MTB/RIF (Xpert) alone in 109 (17.6%), MTBDRplus line probe assay (LPA) alone in 199 (32.0%), and both Xpert and LPA in 134 (21.6%) patients. The coverage rate of mDST has gradually increased to 70% in 2015, 50.7% in 2016, 67.9% in 2017, 75.2% in 2018, and 79.4% in 2019 (P for trend < 0.001). Median time to MDR-TB treatment initiation was 35 days (interquartile range25-75 0-72), which has gradually decreased during the study period (P < 0.001). Independent predictors of shorter time to MDR-TB treatment initiation were retreatment case (adjusted hazard ratio [aHR], 1.30; 95% confidence interval [CI], 1.10-1.54), Xpert testing (aHR, 2.42; 95% CI, 2.03-2.88), and LPA testing (aHR, 1.83; 95% CI, 1.55-2.16). Transfer to another healthcare facility was inversely related to shorter time to treatment initiation (aHR, 0.74; 95% CI, 0.63-0.88).

Conclusion: mDST coverage is gradually increasing and contributes to reducing the time to MDR-TB treatment initiation. Further efforts are needed to achieve universal access to mDST and to properly integrate mDST into routine clinical practice.

Keywords: Drug Resistance; Korea; Multidrug-Resistant Tuberculosis; Time to Treatment; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Annual trends in coverage of mDST (P < 0.001, P for trend < 0.001).
mDST = molecular drug susceptibility testing.
Fig. 2
Fig. 2. Distribution of time to multidrug-resistant tuberculosis treatment initiation.
See this image and copyright information in PMC

References

    1. Nathavitharana RR, Lederer P, Tierney DB, Nardell E. Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(4):396–404. - PMC - PubMed
    1. Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR., Jr Management of drug-resistant tuberculosis. Lancet. 2019;394(10202):953–966. - PMC - PubMed
    1. Cirillo DM, Miotto P, Tortoli E. Evolution of phenotypic and molecular drug susceptibility testing. Adv Exp Med Biol. 2017;1019:221–246. - PubMed
    1. World Health Organization. Policy statement. WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. [Updated 2008]. [Accessed May 30, 2020]. https://www.who.int/tb/features_archive/policy_statement.pdf.
    1. World Health Organization. Policy statement. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. [Updated 2011]. [Accessed May 30, 2020]. https://apps.who.int/iris/bitstream/handle/10665/44586/9789241501545_eng.... - PubMed